HBI Pharma

HUYA Bioscience International (HUYA) is a biopharmaceutical company that specializes in the global development of novel drug candidates sourced from the Chinese life sciences sector. The company employs a unique strategy of identifying high-potential assets in China and advancing them through international clinical and regulatory pathways to reach global markets. Its lead product, Hidaza (HBI-8000), is an oral histone deacetylase (HDAC) inhibitor that has been approved in Japan for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma. HUYA is also developing HBI-3000, a multi-ion channel blocker currently in Phase 2 clinical trials for the treatment of atrial fibrillation. The company maintains a significant operational presence in San Diego, Shanghai, and Tokyo, facilitating cross-border collaborations and licensing deals. Through its proprietary database and extensive network, HUYA continues to build a diverse pipeline of oncology and cardiovascular therapies.